Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody

M. E. Lacouture*, J. M. Baron, A. B. Jani, A. E. Laumann, K. Soltani

*Corresponding author for this work

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Primary cutaneous B cell lymphomas have a high recurrence rate after treatment with surgery and/or local radiation therapy. Two men are described in whom radiotherapy-relapsing cutaneous B-cell lymphomas were successfully treated with the monoclonal anti-CD20 antibody rituximab. Both patients had a complete response with no recurrence at follow-up at 17 and 24 months for the large B-cell lymphoma of the leg and the follicle centre cell lymphoma, respectively. These are two of the few cases in the literature showing that rituximab is an effective and well-tolerated treatment for radiotherapy-relapsing primary cutaneous B cell lymphoma.

Original languageEnglish (US)
Pages (from-to)46-48
Number of pages3
JournalClinical and Experimental Dermatology
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody'. Together they form a unique fingerprint.

  • Cite this